|Bid||0.0000 x 1100|
|Ask||0.0000 x 1300|
|Day's Range||0.4700 - 0.5300|
|52 Week Range||0.2600 - 1.4900|
|Beta (3Y Monthly)||0.93|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 1, 2019 - Aug 5, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||20.00|
Flex Pharma, Inc. (FLKS) today announced that on or about June 27, 2019 it will mail a supplement (the “Supplement”) to its proxy materials to provide stockholders with updated information regarding brokers’ discretionary authority to vote stockholders’ shares on Proposal 2 (regarding the reverse stock split) and Proposal 4 (regarding adjournment of the special meeting). In Flex Pharma’s proxy statement/prospectus/information statement dated April 29, 2019 relating to the special meeting of stockholders (the “Proxy Statement”), Flex Pharma stated that Proposals 1, 2, 3 and 4 in the Proxy Statement are considered non-discretionary matters under the rules of the New York Stock Exchange (“NYSE”) applicable to broker-dealers and, therefore, a stockholder’s broker will not be able to vote the stockholder’s shares of Flex Pharma’s common stock without specific instructions.
Flex Pharma (NASDAQ: FLKS ) shares are trading lower after the company announced more shareholder votes are required to complete its merger with Salarius Pharma despite “overwhelming support.” According ...
Flex Pharma, Inc. (FLKS) today announced that approximately 85% of shares voted to date support the proposed merger with Salarius Pharmaceuticals, LLC, an epigenetic oncology company. Flex Pharma adjourned the special meeting until July 12, 2019 in order to provide shareholders with more time to complete proxies and vote their shares. Flex Pharma’s CEO William McVicar stated, “We are very pleased that the vast majority of shareholders who voted support the merger with Salarius, consistent with the recommendations of both leading, independent proxy advisory services ISS and Glass-Lewis.” Flex Pharma’s Board of Directors also unanimously recommends voting “FOR” all proposals in the proxy statement/prospectus/information statement as the best way to preserve future shareholder value.
Flex Pharma, Inc. (FLKS) today announced that Institutional Shareholder Services Inc. (“ISS”) and Glass Lewis recommend that shareholders vote FOR all agenda items before or at Flex Pharma’s June 14 Special Shareholders Meeting. ISS and Glass Lewis are leading U.S. institutional voting advisory services. Salarius Pharmaceuticals, LLC, is a privately held clinical-stage oncology company targeting the epigenetic causes of cancers.
The Boston-based company said it had a loss of 12 cents per share. Losses, adjusted for stock option expense, were 11 cents per share. The biotech drug developer posted revenue of $105,000 in the period. ...
NEW YORK, NY / ACCESSWIRE / April 26, 2019 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New ...
NEW YORK , April 5, 2019 /PRNewswire/ -- AmpliPhi Biosciences Corporation (APHB) Lifshitz & Miller announces investigation into possible breach of fiduciary duties in connection with the sale of APHB ...
Flex Pharma, Inc. , today announced its financial results for the three months and fiscal year ended December 31, 2018.
Salarius Pharmaceuticals announced plans to merge with Boston-based Flex Pharma Inc. (Nasdaq: FLKS).
NEW YORK , Feb. 26, 2019 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York ...
Houston-based Salarius Pharmaceuticals LLC, a clinical-stage oncology company, will merge with Boston-based Flex Pharma Inc. (Nasdaq: FLKS). The combined company will be named Salarius Pharmaceuticals Inc. and will focus on developing Salarius’ drugs. The deal is expected to close in the first half of 2019, with Flex Pharma stockholders and current Salarius investors owning approximately 19.9 percent and 80.1 percent of the combined company, respectively.
The announcement comes about seven months after Flex Pharma announced it would lay off most of its employees and explore a potential sale or merger after ending a mid-stage trial of its lead drug.
Flex Pharma stock was on the rise today following news of a merger with Salarius Pharmaceuticals. Source: amtec.us.com The deal will have a wholly owned subsidiary of Flex Pharma (NASDAQ:FLKS) merging with Salarius Pharmaceuticals. Once the deal is complete, FLKS will be changing its name to Salarius Pharmaceuticals. When the deal reaches completion, the current management team of Salarius Pharmaceuticals will lead the new company. Flex Pharma's President and CEO William McVicar will also join the company's Board of Directors. InvestorPlace - Stock Market News, Stock Advice & Trading Tips The deal between the two companies will result in holders of Flex Pharma stock having a 19.9% stake in the new company. The remaining will belong to current investors of Salarius Pharmaceuticals. There is also a warrants option for holders of Flex Pharma stock that will allow them an additional 2.4% stake in the company. With the two companies merging to become one, the new focus will be on Salarius Pharmaceuticals pipeline of treatments for orphan cancers and other cancers without treatment options. Money from the combined company is expected to keep it running until mid-2020, which is enough time for it to report "early cohort data from an ongoing Phase 1 Ewing sarcoma trial." * 10 Oversold Stocks Due for a Bounce The deal between Flex Pharma and Salarius Pharmaceuticals already has the unanimous approval from both companies' Board of Directors. It still needs approval from investors in FLKS stock and Salarius Pharmaceuticals, as well as completing other customary closing conditions. If all goes well, the deal is set to close in the first half of 2019. FLKS stock was up 47% as of noon Friday. ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Downtrodden Stocks to Fish From the Bottom * 8 Cheap Value Stocks That Just Got More Enticing * 5 Apple Suppliers Hurt by the Guidance Cut As of this writing, William White did not hold a position in any of the aforementioned securities. Compare Brokers The post FLKS News: Flex Pharma Stock Rockets Higher on Salarius Merger appeared first on InvestorPlace.
Embattled Flex Pharma Inc (NASDAQ: FLKS) announced a deal Friday to merge with privately held Salarius Pharma, an oncology company targeting the epigenetic causes of cancer. Following the closing of the deal, Flex shareholders would own about 19.9 percent of the combined company and Salarius shareholders the remaining 80.1 percent. Flex shareholders would also receive a right to receive warrants six months and a day after the closing of the deal, which gives them the option to purchase additional shares.
CORAL GABLES, FL / ACCESSWIRE / January 4, 2019 / As we close out the week of the first few days of the new year, The health care industry is booming with companies determined to use inventive approaches to develop quality treatment options for patients around the world. Premier Health Group (PHGRF) (PHGI), Flex Pharma, Inc. (NASDAQ: FLKS), Ampliphi Biosciences Corp (NYSE American: APHB), and Histogenics Corp (NASDAQ: HSGX) are 4 healthcare stocks worth checking out on Friday. Premier Health Group (PHGRF) (PHGI) enjoyed impressive gains as shares closed out Thursday's trading at $0.66 per share, up more than 7% from December 27's close of $0.62 per share.
Flex Pharma, Inc. Management believes that the proposed transaction will position the combined company to recognize multiple value inflection points based on Salarius’ clinical pipeline, which targets rare, orphan cancers with no targeted treatments and cancers that have a high unmet need. Salarius recently completed a $6.4 million private placement, which combined with cash from Flex Pharma is expected to fund the combined company to mid-2020, allowing it to report early cohort data from an ongoing Phase 1 Ewing sarcoma trial.
If you're interested in Flex Pharma, Inc. (NASDAQ:FLKS), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could Read More...
Asceneuron, an emerging leader in the development of innovative small molecules for the treatment of neurodegenerative diseases, announced today the appointment of Thomas C. Wessel, MD, PhD, as Chief Medical Officer. Tom has over 20 years of experience in the biopharmaceutical industry and will be responsible for progressing the development of Asceneuron's lead program ASN120290 and a pipeline of novel small molecules through the clinic. Tom will be based at Asceneuron's new offices in Cambridge, Massachusetts, where he will lead all regulatory and clinical development activities as part of the company's further expansion in the United States.
NEW YORK, Nov. 13, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
The Boston-based company said it had a loss of 15 cents per share. The biotech drug developer posted revenue of $251,000 in the period. The company's shares closed at 63 cents. A year ago, they were trading ...
CORAL GABLES, FL / ACCESSWIRE / October 29,2018 / Frost & Sullivan will be hosting a Growth Innovation Leadership (GIL) briefing titled "2019 Healthcare Predictions Unleashed - Growth Opportunities, Technology, and Trends." The firm already states that Globally, 2019 will be a year of value-based care as we expect the outcomes-based care focus to globalize. "The HealthVue patient app powered by Reliq Health's technology platform will allow patients to book appointments, see their GP or a specialist via telemedicine, review their own chart, chat with clinic staff and pharmacists, refill prescriptions and share health data collected in the home with their HealthVue care team," said Dr. Essam Hamza, MD, CEO of HealthVue.
NEW YORK, NY / ACCESSWIRE / October 22, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Flex Pharma, Inc. (FLKS) a biotechnology company focused on developing innovative and proprietary treatments for muscle cramps, spasms, and spasticity associated with severe neurological conditions. Earlier this year the company stopped its clinical trials of FLX-787 in MND and CMT and is the process of winding down those studies. Management cited the cost of continued clinical trials as the reason.